Patrone et al study the mechanism by which fingolimod, a drug used for multiple sclerosis, and agonist to G-coupled receptor S1PR1, compared to the endogenous ligand S1P. They find that whereas S1P binds a S1PR1 dimer, the action of fingolimod is dependent on receptor oligomerisation, which affects β-arrestin binding, internalisation and signaling.
- Marco Patrone
- Eugenia Cammarota
- Massimo Degano
